Event JSON
{
"id": "5eaa3c5f2f42aa660541749e2054dd48f4a65ddc25b76f845d54ac659e5027d7",
"pubkey": "523e7d5b69a98a9c3374105934ca42aa132465e5f899713127ffbc843532945c",
"created_at": 1750205501,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/china-pharma-projects-disrupted-sino-230956208.html"
],
[
"subject",
"China pharma projects disrupted by Sino-US tensions"
],
[
"published_at",
"1750201796"
],
[
"image",
"https://media.zenfs.com/en/reuters-finance.com/97836c691f956c3700d63427c5f99b13"
],
[
"p",
"523e7d5b69a98a9c3374105934ca42aa132465e5f899713127ffbc843532945c",
"wss://relay-testnet.k8s.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/reuters-finance.com/97836c691f956c3700d63427c5f99b13"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"As US-China trade tensions escalate, Chinese firms are taking precautions to mitigate the impact. They are stockpiling supplies, discussing testing clinical samples locally instead of sending them to China, and pausing or delaying projects. This is due to concerns about delays in accessing US supply chains, increased costs, and uncertainty about future trade policies."
]
],
"content": "nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgzj8e74k6df32wrxaqsty6v5s42zvjxte0cn9cnzfllhjzr2v55tssjpv34\nhttps://media.zenfs.com/en/reuters-finance.com/97836c691f956c3700d63427c5f99b13\n\nhttps://finance.yahoo.com/news/china-pharma-projects-disrupted-sino-230956208.html",
"sig": "2180835b7263cdfb81592840c52f30ba0607303a5744e95298317c1e2b02660f17253b2d6afaa9b8569bd244a46718b0aefa53dcd41c4f190e75ec88106af82a"
}